Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 599

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 599
---
 possible redemption are presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets, respectively.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to difference between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed to be de minimis as of December 31, 2023 and 2022.

|                          |     | Year ended   
 December 31, 
 2023         |         |
|:-------------------------|:----|:-------------|--------:|
| Income tax expense:      |     |              |         |
| Federal                  |     | $            | 540,811 |
| State                    |     |              |       — |
| Total income tax expense |     | $            | 540,811 |

|                                                      |     |   Year ended 
 December 31, 
         2023 |   |
|:-----------------------------------------------------|:----|-------------:|:--|
| Income tax expense:                                  |     |              |   |
| Provision/(Benefit) at Statutory Rate                |     |         21.0 | % |
| State Tax Provision/(Benefit) net of federal benefit |     |          0.0 | % |
| Change in FV of Warrants                             |     |          0.0 | % |
| Change in valuation                                  |     |          0.0 | % |
| Other                                                |     |          0.0 | % |
| Total income tax expense                             |     |         21.0 | % |

F-39 BELLEVUE LIFE SCIENCES ACQUISITION CORP.
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 2023 NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) ASC 740 prescribes a recognition threshold and a measurement attribute for